CYP4V2 and neoplasm: In the present study, we utilised 5HREp (Shibata et al, 2000) and a prodrug-activating gene, bacterial cytosine deaminase (BCD) (Mullen et al, 1992; Miller et al, 2002), and successfully established an adenovirus-mediated gene therapy strategy for tumour hypoxia.